Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 10/20 | 0.46 |
| ▸ | NEK2 | P51955 | 4/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3253677 | 1.00 | PLK1 (0.46) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL3255741 | 0.95 | PLK1 (0.51) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL13440197 | 0.95 | PLK1 (0.51) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL3258526 | 0.94 | PLK1 (0.47) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL13440202 | 0.94 | PLK1 (0.47) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL13440230 | 0.92 | PLK1 (0.51) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL3259784 | 0.92 | PLK1 (0.51) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL3257193 | 0.91 | PLK1 (0.45) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL3267248 | 0.91 | PLK1 (0.45) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4355484 | 0.91 | PLK1 (0.48) | PLK1PLK3NEK2PIK3CDNUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2009-05-14 | — | — | US | disclosed |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | PLK1 458/4885PLK3 1235/4885NEK2 2703/4885 |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | PLK1 458/4885PLK3 1235/4885NEK2 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.